Thrombocytopenia in ill children is common; accurately diagnosing the underlying etiology is challenging and essential for appropriate management. Triggers for accelerated consumption of platelets are numerous; common downstream mechanisms of clearance include platelet trapping in microvascular thrombi, phagocytosis, and platelet activation. Thrombocytopenia with microangiopathic hemolytic anemia (MAHA) is frequently due to disseminated intravascular coagulation. Thrombotic microangiopathy (TMA) is a subgroup of MAHA. Specific TMA syndromes include thrombotic thrombocytopenic purpura, complement-mediated TMA (CM-TMA), and Shiga toxin–mediated hemolytic uremic syndrome. Isolated thrombocytopenia is characteristic of immune thrombocytopenia; however, concomitant cytopenias are frequent in critically ill patients, making the diagnosis difficult. Immune thrombocytopenia with large vessel thrombosis is a feature of heparin-induced thrombocytopenia and antiphospholipid antibody syndrome. In addition, thrombocytopenia is common with macrophage activation, which is characteristic of hemophagocytic lymphohistiocytosis. While thrombocytopenia in ill patients can be driven by hypoproliferative processes such as myelosuppression and/or bone marrow failure, this review will focus on consumptive thrombocytopenia due to immune and nonimmune causes.

1.
Arepally
GM
.
Heparin-induced thrombocytopenia
.
Blood
.
2017
;
129
(
21
):
2864
-
2872
.
doi:10.1182/blood-2016-11-709873
.
2.
Cuker
A
,
Arepally
GM
,
Chong
BH
, et al.
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
.
Blood Adv
.
2018
;
2
(
22
):
3360
-
3392
.
doi:10.1182/bloodadvances.2018024489
.
3.
Obeng
EA
,
Harney
KM
,
Moniz
T
,
Arnold
A
,
Neufeld
EJ
,
Trenor CC
III
.
Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system
.
J Pediatr
.
2015
;
166
(
1
):
144
-
150
.
doi:10.1016/j.jpeds.2014.09.017
.
4.
Cohen
O
,
Lange
K
,
Budnik
I
, et al.
Application of a clinical decision rule and laboratory assays in pediatrics: adult heparin-induced thrombocytopenia
.
Pediatr Blood Cancer
.
2022
;
69
(
11
):
e29929
.
doi:10.1002/pbc.29929
.
5.
Takemoto
CM
,
Streiff
MB
.
Heparin-induced thrombocytopenia screening and management in pediatric patients
.
Hematology Am Soc Hematol Educ Program
.
2011
;
2011
:
162
-
169
.
doi:10.1182/asheducation-2011.1.162
.
6.
Cuker
A
,
Cines
DB
.
How I treat heparin-induced thrombocytopenia
.
Blood
.
2012
;
119
(
10
):
2209
-
2218
.
doi:10.1182/blood-2011-11-376293
.
7.
Lo
GK
,
Juhl
D
,
Warkentin
TE
,
Sigouin
CS
,
Eichler
P
,
Greinacher
A.
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings
.
J Thromb Haemost
.
2006
;
4
(
4
):
759
-
765
.
doi:10.1111/j.1538-7836.2006.01787.x
.
8.
Avila
L
,
Amiri
N
,
Yenson
P
, et al.
Heparin-induced thrombocytopenia in a pediatric population: implications for clinical probability scores and testing
.
J Pediatr
.
2020
;
226
:
167
-
172.e2172e2
.
doi:10.1016/j.jpeds.2020.06.081
.
9.
Cuker
A.
Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach
.
Semin Thromb Hemost
.
2014
;
40
(
1
):
106
-
114
.
doi:10.1055/s-0033-1363461
.
10.
Whitlatch
NL
,
Perry
SL
,
Ortel
TL
.
Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia
.
Thromb Haemost
.
2008
;
100
(
4
):
678
-
684
.
doi:10.1160/th08-02-0118
.
11.
Samuelson Bannow
B
,
Warad
DM
,
Jones
CG
, et al.
A prospective, blinded study of a PF4-dependent assay for HIT diagnosis
.
Blood
.
2021
;
137
(
8
):
1082
-
1089
.
doi:10.1182/blood.2020008195
.
12.
Chandrakasan
S
,
Chandra
S
,
Davila Saldana
BJ
,
Torgerson
TR
,
Buchbinder
D.
Primary immune regulatory disorders for the pediatric hematologist and oncologist: a case-based review
.
Pediatr Blood Cancer
.
2019
;
66
(
5
):
e27619
.
doi:10.1002/pbc.27619
.
13.
Reese
JA
,
Muthurajah
DS
,
Kremer Hovinga
JA
,
Vesely
SK
,
Terrell
DR
,
George
JN
.
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features
.
Pediatr Blood Cancer
.
2013
;
60
(
10
):
1676
-
1682
.
doi:10.1002/pbc.24612
.
14.
Siddiqui
A
,
Journeycake
JM
,
Borogovac
A
,
George
JN
.
Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children
.
Pediatr Blood Cancer
.
2021
;
68
(
5
):
e28949
.
doi:10.1002/pbc.28949
.
15.
Bendapudi
PK
,
Hurwitz
S
,
Fry
A
, et al.
Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study
.
Lancet Haematol
.
2017
;
4
(
4
):
e157
-
e164
.
doi:10.1016/S2352-3026(17)30026-1
.
16.
Rairikar
M
,
Sartain
SE
,
Solomon
C
,
Hui
S-KR
,
Srivaths
P.
Plasmic (PLASMICkid) score for pediatric thrombotic thrombocytopenic purpura
.
Blood
.
2022
;
140
(
suppl 1
):
11346
-
11347
.
doi:10.1182/blood-2022-170608
.
17.
Zheng
XL
,
Vesely
SK
,
Cataland
SR
, et al.
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura
.
J Thromb Haemost
.
2020
;
18
(
10
):
2496
-
2502
.
doi:10.1111/jth.15010
.
18.
Peyvandi
F
,
Scully
M
,
Kremer Hovinga
JA
, et al
;
TITAN Investigators
.
Caplacizumab for acquired thrombotic thrombocytopenic purpura
.
N Engl J Med
.
2016
;
374
(
6
):
511
-
522
.
doi:10.1056/NEJMoa1505533
.
19.
Scully
M
,
Cataland
SR
,
Peyvandi
F
, et al
;
HERCULES Investigators
.
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
.
N Engl J Med
.
2019
;
380
(
4
):
335
-
346
.
doi:10.1056/NEJMoa1806311
.
20.
Dutt
T
,
Shaw
RJ
,
Stubbs
M
, et al.
Real-world experience with caplacizumab in the management of acute TTP
.
Blood
.
2021
;
137
(
13
):
1731
-
1740
.
doi:10.1182/blood.2020007599
.
21.
George
JN
,
Nester
CM
.
Syndromes of thrombotic microangiopathy
.
N Engl J Med
.
2014
;
371
(
7
):
654
-
666
.
doi:10.1056/NEJMra1312353
.
22.
Scully
M
,
Cataland
S
,
Coppo
P
, et al
;
International Working Group for Thrombotic Thrombocytopenic Purpura
.
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
.
J Thromb Haemost
.
2017
;
15
(
2
):
312
-
322
.
doi:10.1111/jth.13571
.
23.
Jodele
S
,
Laskin
BL
,
Dandoy
CE
, et al.
A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi- system endothelial injury
.
Blood Rev
.
2015
;
29
(
3
):
191
-
204
.
doi:10.1016/j.blre.2014.11.001
.
24.
Meri
S
,
Bunjes
D
,
Cofiell
R
,
Jodele
S.
The role of complement in HSCT-TMA: basic science to clinical practice
.
Adv Ther
.
2022
;
39
(
9
):
3896
-
3915
.
doi:10.1007/s12325-022-02184-4
.
25.
Riedl
M
,
Fakhouri
F
,
Le Quintrec
M
, et al.
Spectrum of complement- mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches
.
Semin Thromb Hemost
.
2014
;
40
(
4
):
444
-
464
.
doi:10.1055/s-0034-1376153
.
26.
Goodship
TH
,
Cook
HT
,
Fakhouri
F
, et al
;
Conference Participants
.
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) Controversies Conference
.
Kidney Int
.
2017
;
91
(
3
):
539
-
551
.
doi:10.1016/j.kint.2016.10.005
.
27.
Gavriilaki
E
,
de Latour
RP
,
Risitano
AM
.
Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond
.
Blood
.
2022
;
139
(
25
):
3571
-
3582
.
doi:10.1182/blood.2021012860
.
28.
Levi
M
,
Sivapalaratnam
S.
Disseminated intravascular coagulation: an update on pathogenesis and diagnosis
.
Expert Rev Hematol
.
2018
;
11
(
8
):
663
-
672
.
doi:10.1080/17474086.2018.1500173
.
29.
Gando
S
,
Levi
M
,
Toh
C-H
.
Disseminated intravascular coagulation
.
Nat Rev Dis Primers
.
2016
;
2
:
16037
.
doi:10.1038/nrdp.2016.37
.
30.
Nguyen
TC
.
Thrombocytopenia-associated multiple organ failure
.
Crit Care Clin
.
2020
;
36
(
2
):
379
-
390
.
doi:10.1016/j.ccc.2019.12.010
.
31.
Price
VE
,
Ledingham
DL
,
Krümpel
A
,
Chan
AK
.
Diagnosis and management of neonatal purpura fulminans
.
Semin Fetal Neonatal Med
.
2011
;
16
(
6
):
318
-
322
.
doi:10.1016/j.siny.2011.07.009
.
32.
Wada
H
,
Thachil
J
,
Di Nisio
M
, et al.
Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines
.
J Thromb Haemost
.
2013
;
11
(
4
):
761
-
767
.
doi:10.1111/jth.12155
.
33.
Taylor
FB
Jr
,
Toh
CH
,
Hoots
WK
,
Wada
H
,
Levi
M
;
Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH)
.
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation
.
Thromb Haemost
.
2001
;
86
(
5
):
1327
-
1330
.
34.
Rajagopal
R
,
Thachil
J
,
Monagle
P.
Disseminated intravascular coagulation in paediatrics
.
Arch Dis Child
.
2017
;
102
(
2
):
187
-
193
.
doi:10.1136/archdischild-2016-311053
.
35.
Jhang
WK
,
Ha
EJ
,
Park
SJ
.
Evaluation of disseminated intravascular coagulation scores in critically ill pediatric patients
.
Pediatr Crit Care Med
.
2016
;
17
(
5
):
e239
-
e246
.
doi:10.1097/PCC.0000000000000705
.
36.
Soundar
EP
,
Jariwala
P
,
Nguyen
TC
,
Eldin
KW
,
Teruya
J.
Evaluation of the International Society on Thrombosis and Haemostasis and institutional diagnostic criteria of disseminated intravascular coagulation in pediatric patients
.
Am J Clin Pathol
.
2013
;
139
(
6
):
812
-
816
.
doi:10.1309/AJCPO64IWNLYCVVB
.
37.
Levi
M
,
Toh
CH
,
Thachil
J
,
Watson
HG
.
Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology
.
Br J Haematol
.
2009
;
145
(
1
):
24
-
33
.
doi:10.1111/j.1365-2141.2009.07600.x
.
38.
Jordan
MB
,
Allen
CE
,
Greenberg
J
, et al.
Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)
.
Pediatr Blood Cancer
.
2019
;
66
(
11
):
e27929
.
doi:10.1002/pbc.27929
.
39.
Gloude
NJ
,
Dandoy
CE
,
Davies
SM
, et al.
Thinking beyond HLH: clinical features of patients with concurrent presentation of hemophagocytic lymphohistiocytosis and thrombotic microangiopathy
.
J Clin Immunol
.
2020
;
40
(
5
):
699
-
707
.
doi:10.1007/s10875-020-00789-4
.
You do not currently have access to this content.